Conmed (CNMD) Research & Development (2010 - 2026)

Conmed (CNMD) has reported Research & Development for 17 consecutive years, with $15.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Research & Development rose 9.63% year-over-year to $15.5 million; the trailing twelve-month figure through Jun 2026 stood at $60.6 million (up 12.66% YoY), and the FY2025 full-year result was $55.9 million, up 2.68% from the prior year.
• Research & Development declined to $15.5 million in Q2 2026 per CNMD's latest filing, from $16.3 million in the prior quarter.
• Across five years, Research & Development topped out at $16.3 million in Q1 2026 and bottomed at $10.7 million in Q1 2022.
• Historically, Research & Development has averaged $13.4 million across 5 years, with a median of $13.6 million in 2023.
• The sharpest annual moves came in 2024 and 2026: Research & Development fell 6.07% in 2024, then gained 26.15% in 2026.
• Over 5 years, Research & Development stood at $12.2 million in 2022, then rose by 14.8% to $14.0 million in 2023, then dropped by 6.07% to $13.2 million in 2024, then advanced by 13.08% to $14.9 million in 2025, then rose by 4.03% to $15.5 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $15.5 million, $16.3 million, and $14.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.